News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Filipa Lynce

Articles by Filipa Lynce

TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)

ByBOLDSCIENCE,Pedram Razavi,Judith Balmaña,Stephen Luen,Mario Campone,Laura Cortesi,Norikazu Masuda,Kyong Hwa Park,Qingyuan Zhang,Emily Nizialek,Cathy Qi,Karen Cui,Sibylle Loibl,Mark Robson, MD,Filipa Lynce

April 22nd 2025

Latest Updated Articles

Trending on CancerNetwork

FDA OKs Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma

Evaluating the Viability of Antibody Drug Conjugates for Glioblastoma

Could Scorpion Venom Component Play a Role in Glioblastoma Management?

FDA Approves Abbreviated NDA for Dasatinib Tablets in Leukemia Indications

Daratumumab Approval May Be “Game Changer” in High-Risk Smoldering Myeloma

© 2025 MJH Life Sciences^®

All rights reserved.